Physician profile
Phillip Amodeo
NPI 1609064146
$32,586.01
in general payments reported to CMS, 2019-2025
62 companies · $2,809 in 2025
The $2,809 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,878 · 2020: $6,184 · 2021: $16K · 2022: $1,762 · 2023: $1,978 · 2024: $2,425 · 2025: $2,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,212.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,232.61 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Allergan, INC. | $8,180.95 | 2019-2022 | |
| Ucb, INC. | $679.09 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Lundbeck LLC | $608.39 | 2019-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $608.11 | 2019-2025 | Ultomiris |
| Pfizer INC. | $573.42 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $561.66 | 2019-2025 | |
| Argenx US, INC. | $447.19 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $437.21 | 2019-2025 | Hizentra |
| Adamas Pharmaceuticals, INC. | $428.26 | 2019-2021 | |
| Emd Serono, INC. | $404.98 | 2019-2024 | Mavenclad |
| Genentech USA, INC. | $392.16 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Sk Life Science, INC. | $369.49 | 2020-2025 | |
| Lilly USA, LLC | $362.15 | 2019-2025 | Amyvid, Reyvow, Emgality |
| Amgen INC. | $330.53 | 2019-2025 | Uplizna |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Amodeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.